Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR3 | Q9UBY5 | 12/20 | 0.68 |
| ▸ | LPAR1 | Q92633 | 10/20 | 0.68 |
| ▸ | LPAR2 | Q9HBW0 | 5/20 | 0.50 |
| ▸ | LPAR5 | Q9H1C0 | 3/20 | 0.50 |
| ▸ | ENPP2 | Q13822 | 5/20 | 0.46 |
| ▸ | LPAR6 | P43657 | 2/20 | 0.46 |
| ▸ | LPAR4 | Q99677 | 2/20 | 0.46 |
| ▸ | TLR2 | O60603 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5081834 | 1.00 | LPAR3 (0.68) | LPAR3LPAR1LPAR2LPAR5ENPP2 | |
| SCHEMBL14032166 | 1.00 | LPAR3 (0.68) | LPAR3LPAR1LPAR2LPAR5ENPP2 | |
| SCHEMBL11082621 | 0.92 | LPAR3 (0.57) | LPAR3LPAR1LPAR2LPAR5ENPP2 | |
| SCHEMBL11079228 | 0.92 | LPAR3 (0.57) | LPAR3LPAR1LPAR2LPAR5ENPP2 | |
| SCHEMBL11083607 | 0.91 | LPAR3 (0.56) | LPAR3LPAR1LPAR2LPAR5ENPP2 | |
| SCHEMBL11091806 | 0.91 | LPAR3 (0.56) | LPAR3LPAR1LPAR2LPAR5ENPP2 | |
| SCHEMBL11081544 | 0.90 | LPAR3 (0.54) | LPAR3LPAR1LPAR2LPAR5ENPP2 | |
| SCHEMBL4747959 | 0.90 | LPAR3 (0.54) | LPAR3LPAR1LPAR2LPAR5ENPP2 | |
| SCHEMBL11088254 | 0.90 | LPAR3 (0.54) | LPAR3LPAR1LPAR2LPAR5ENPP2 | |
| SCHEMBL11079136 | 0.90 | LPAR3 (0.54) | LPAR3LPAR1LPAR2LPAR5ENPP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021198725-A1 | FOSALVUDINE AND FOZIVUDINE TIDOXIL FOR USE IN THE TREATMENT OF COVID-19, AND USE OF THE STRUCTURALLY SIMPLIFIED DERIVATIVES THEREOF | CHIRACON GMBH (DE) | 2021-10-07 | — | — | WO | disclosed |
| US-20170183373-A1 | NUCLEOSIDE DERIVATIVES AS INHIBITORS OF RNA-DEPENDENT RNA VIRAL POLYERMASE | MERCK SHARP & DOHME CORP. (US) | 2017-06-29 | — | — | US | disclosed |
| US-20140309412-A1 | NUCLEOSIDE DERIVATIVES AS INHIBITORS OF RNA-DEPENDENT RNA VIRAL POLYMERASE | IONIS PHARMACEUTICALS, INC. | 2014-10-16 | — | — | US | disclosed |
| US-8481712-B2 | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase | MERCK SHARP & DOHME CORP. (US) | 2013-07-09 | — | — | US | disclosed |
| US-20120165515-A1 | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase | MERCK SHARP & DOHME LLC | 2012-06-28 | — | — | US | disclosed |
| EP-2399588-A1 | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase | Merck Sharp & Dohme Corp. (US) | 2011-12-28 | — | — | EP | disclosed |
| EP-2360166-A1 | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase | Merck Sharp & Dohme Corp. (US) | 2011-08-24 | — | — | EP | disclosed |
| US-20080249066-A1 | ANTIVIRAL COMPOUNDS AND COMPOSITIONS | ARDEA BIOSCIENCES, INC. (US) | 2008-10-09 | — | — | US | disclosed |
| US-20080249066-A1 | ANTIVIRAL COMPOUNDS AND COMPOSITIONS | ARDEA BIOSCIENCES, INC. (US) | 2008-10-09 | — | — | US | disclosed |
| US-7419965-B2 | Nucleotide lipid ester derivatives | HEIDELBERG PHARMA AG (DE) | 2008-09-02 | — | — | US | disclosed |
| US-20040110717-A1 | Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase | MERCK SHARP & DOHME LLC | 2004-06-10 | — | — | US | disclosed |
| US-20040072788-A1 | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase | BHAT BALKRISHEN (US) | 2004-04-15 | — | — | US | disclosed |
| US-20040067901-A1 | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase | MERCK SHARP & DOHME LLC | 2004-04-08 | — | — | US | disclosed |
| US-20020147160-A1 | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase | MERCK SHARP & DOHME LLC | 2002-10-10 | — | — | US | disclosed |
| WO-2002057425-A2 | NUCLEOSIDE DERIVATIVES AS INHIBITORS OF RNA-DEPENDENT RNA VIRAL POLYMERASE | MERCK & CO., INC. (US) | 2002-07-25 | — | — | WO | disclosed |
| EP-0741740-B1 | METHOD OF PREPARING UNSYMMETRICAL PHOSPHORIC ACID DIESTERS AND SALTS | ROCHE DIAGNOSTICS GMBH (DE) | 1999-04-07 | — | — | EP | disclosed |
| US-5734042-A | Process for the production of asymmetrical phosphoric acid diesters | BOEHRINGER MANNHEIM GMBH (DE) | 1998-03-31 | — | — | US | disclosed |
| EP-0741740-A1 | METHOD OF PREPARING UNSYMMETRICAL PHOSPHORIC ACID DIESTERS AND SALTS | Roche Diagnostics GmbH (DE) | 1996-11-13 | — | — | EP | disclosed |
| WO-1995020596-A1 | METHOD OF PREPARING UNSYMMETRICAL PHOSPHORIC ACID DIESTERS | BOEHRINGER MANNHEIM GMBH (DE) | 1995-08-03 | — | — | WO | disclosed |
| EP-0545966-A1 | NEW PHOSPHOLIPID DERIVATIVES OF NUCLEOSIDES, THEIR PREPARATION AND THEIR USE AS ANTIVIRAL DRUGS. | BOEHRINGER MANNHEIM GMBH (DE) | 1993-06-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040067901-A1 | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase | NSUN2, NSUN3, POLRMT | LPAR3 1491/4885LPAR1 1790/4885LPAR2 2624/4885 |
| US-20080249066-A1 | ANTIVIRAL COMPOUNDS AND COMPOSITIONS | PNP, TYMP, MTAP | LPAR3 1438/4885LPAR1 1211/4885LPAR2 2035/4885 |
| US-20040110717-A1 | Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase | NSUN2, NSUN3, POLRMT | LPAR3 1766/4885LPAR1 2125/4885LPAR2 2978/4885 |
| US-20170183373-A1 | NUCLEOSIDE DERIVATIVES AS INHIBITORS OF RNA-DEPENDENT RNA VIRAL POLYERMASE | POLRMT, DUT, RNASE1 | LPAR3 2811/4885LPAR1 3256/4885LPAR2 3932/4885 |
| US-20040072788-A1 | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase | NSUN2, NSUN3, POLRMT | LPAR3 1491/4885LPAR1 1790/4885LPAR2 2624/4885 |
| US-20140309412-A1 | NUCLEOSIDE DERIVATIVES AS INHIBITORS OF RNA-DEPENDENT RNA VIRAL POLYMERASE | NSUN2, NSUN3, POLRMT | LPAR3 1491/4885LPAR1 1790/4885LPAR2 2624/4885 |
| US-20020147160-A1 | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase | NSUN2, NSUN3, POLRMT | LPAR3 1491/4885LPAR1 1790/4885LPAR2 2624/4885 |
| US-20120165515-A1 | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase | NSUN2, NSUN3, POLRMT | LPAR3 1491/4885LPAR1 1790/4885LPAR2 2624/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.